Primary lateral sclerosis (PLS) is a motor neuron disease that occurs when the nerve cells in muscles slowly deteriorate. This leads to weakness in the voluntary muscles like the tongue ...

The primary market drivers focus on global business expansion. Additionally, the report presents trends, advancements, material insights, technological developments, and the evolving market structure.

Incorrect identification of ALS cases is still possible within the UK Biobank due to the reliance on record linkage and the use of ICD10 and ICD9 codes that encompass non-ALS motor neuron diseases ...

In a small human trial in SMA patients neurostimulation sessions improved motoneuron function, reduced fatigue, and improved leg muscle strength and walking.

HB-adMSCs is under clinical development by Hope Biosciences and currently in Phase I for Primary Lateral Sclerosis. According to GlobalData, Phase I drugs for Primary Lateral Sclerosis does not have ...

Western student applying occupational therapy to her ALS experience to help other families manage their daily lives with physical or cognitive impairment.

Ncardia, a global leader in human induced pluripotent stem cell (hiPSC) technology, today announced the launch of Ncyte® Microglia, a groundbreaking tool to advance research in neurodegenerative ...

Methods Cohort recruited via a specialist, multidisciplinary clinic. Patients were categorised into four clinical phenotypes (ALS, flail arm, flail leg and primary lateral sclerosis) according to site ...

Zydus Life share rose after it received approval from USFDA to conduct Phase II(b) clinical trial for Usnoflast, a novel oral NLRP3 inflammasome inhibitor in patients with ALS ...

Ncardia’s iPSC-derived microglia may aid ALS research and help to screen new therapies that target inflammation in ALS.